Table 4 The relationship between potential confounding factors and post-cisplatin acute kidney injury
Variables | Post chemotherapy AKI (%) | p | |
|---|---|---|---|
Yes | No | ||
Age | |||
  < 40 years old | 10.3 | 89.7 | 0.149 |
  ≥ 40 years old | 21.1 | 78.9 | |
Sex | |||
 Male | 18.5 | 81.5 | 0.692 |
 Female | 15.6 | 84.4 | |
Type of Cancer | |||
 Nasopharyngeal | 18.0 | 82.0 | 0.467 |
 Head and neck other than nasopharyngeal | 7.1 | 92.9 | |
 Osteosarcoma | 9.1 | 90.9 | |
 Others | 25 | 75 | |
Regimen of Chemotherapy | |||
 5FU | 26.5 | 73.5 | 0.146 |
 Docetaxel | 10.5 | 89.5 | |
 Paclitaxel | 10.0 | 90.0 | |
 Doxorubicin | 0 | 100 | |
 Others | 13.6 | 86.4 | |
Dose of Cisplatin (mg/m2) | |||
 100 | 10.3 | 89.7 | 0.525 |
 80 | 0 | 100 | |
 75 | 21.6 | 78.4 | |
Cycle of Chemotherapy | |||
 1st | 16.2 | 83.8 | 1.00 |
 2 nd | 21.7 | 78.3 | |
 3 rd | 20.0 | 80.0 | |
 4 th | 0 | 100 | |
Diabetes Mellitus | 0 | 100 | 1.00 |
 No DM | 17.8 | 82.2 |  |
Hypertension | 36.4 | 63.6 | 0.942 |
 No Hypertension | 15.2 | 84.8 |  |
Concomitant Radiotherapy | |||
 Yes | 11.1 | 89.8 | 0.734 |
 No | 18.5 | 81.5 | |